- TLDR Biotech
- Archive
- Page 8
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | June 12 - 13, 2024
Pfizer's DMD hopes shattered in Ph3 (while also planning for 8 blockbusters by 2030), while JP Morgan closes $500M biotech fund, a new antibody player launches with $168M, and Eli Lilly gets an upgrade (from accelerated to full approval)
Biotech & Pharma Updates | June 11 - 12, 2024
BMS still has an M&A appetite, Ultragenyx has some bone-building Ph2/3 results, Eli Lilly's Alzheimer's approval could be good news for rivals Biogen and Eisai too, Foresite Capital raises a $900M life science fund, and Pfizer signs a discovery pact with ProFound Therapeutics in search of the next great obesity med
Biotech & Pharma Updates | June 5 - 6, 2024
Boehringer & Zealand Pharma Ph2 NASH data "unintentionally" published early, Seres Therapeutics sells a commercial asset to stay afloat, Abbvie's $10.1B ImmunoGen acquisition delivers Ph2 win, Nucleus RadioPharma fundraise, and Structure Therapeutics hopes to ride the data wave to a $476M stock sale